Elite Pharma,der zock beginnt !
Seite 1 von 2 Neuester Beitrag: 19.04.11 18:47 | ||||
| Eröffnet am: | 12.04.11 16:53 | von: Chalifmann3 | Anzahl Beiträge: | 36 |
| Neuester Beitrag: | 19.04.11 18:47 | von: wes_ | Leser gesamt: | 6.146 |
| Forum: | Hot-Stocks | Leser heute: | 16 | |
| Bewertet mit: |  | |||
| Seite: < | 2 > | ||||
Elite Pharma (OTCBB:ELTP)
Intraday Stock Chart
Today : Tuesday 11 January 2011
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) and Hi-Tech Pharmacal Co., Inc. ("Hi-Tech) (Nasdaq:HITK) today announced that they have entered into an agreement for Elite to develop for Hi-Tech an intermediate for a generic version of a prescription product for which the branded product had sales in 2010 of over $100 million.
Under the terms of the agreement, Elite will undertake a developmental program for an intermediate product that Hi-Tech shall then incorporate into a final product. Hi-Tech, or its designees, shall be responsible for the filing of the Abbreviated New Drug Application ("ANDA") for the finished product and the ANDA will be filed under the Hi-Tech name. Upon approval of the ANDA, Elite will manufacture the intermediate product. Hi-Tech will manufacture the final product and will be responsible for the marketing and sales of the final product. Hi-Tech will pay Elite milestone payments for the development work. Upon commercialization, Elite will receive payment for the manufacturing of the intermediate product and a percentage of the profits generated from the sale of the product.
About Hi-Tech Pharmacal Co., Inc.
Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing generic and branded prescription and OTC products. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company's Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace. Hi-Tech's ECR Pharmaceuticals subsidiary markets branded prescription products.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Two of Elite's products, Lodrane 24® and Lodrane 24D®, are marketed by a partner, ECR Pharmaceuticals, for allergy treatment. Elite's lead pipeline products are novel sustained release oral formulations of oxycodone for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Both products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are in late-stage development. Elite, with partners, also has an ANDA filed with the FDA for a generic equivalent of a pain product and has a generic gastrointestinal drug product in clinical development. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
MFG
Chali
Optionen
| Boardmail an "Chalifmann3" |
Wertpapier: Elite Pharmaceuticals |
Angehängte Grafik:
a015.gif
a015.gif
NORTHVALE, N.J., April 7, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP - News) announced today that the initial shipment of phentermine HCl 37.5 mg tablets, the generic version of Adipex-P(R) 37.5 mg tablets, was made, triggering a milestone payment under the License, Manufacturing and Supply Agreement with Precision Dose and its wholly owned subsidiary TAGI Pharma, Inc. TAGI Pharma will distribute the product as part of a multi-product distribution agreement.
Phentermine HCl is a member of the amphetamine and phenethylamine class. It is an appetite suppressant used to help reduce weight in obese patients when used short-term and combined with exercise, diet, and behavioral modification.
For the most recent twelve months ending December 2010, Adipex-P(R) and its generics had total U.S. sales of approximately $40 million according to IMS Health Data.
About TAGI Pharma, Inc.
TAGI Pharma was launched by Precision Dose in 2010 as a specialty pharmaceutical company focused on the Retail Market Segment. A key component of TAGI Pharma's strategy is the leveraging of its sales and distribution core competencies with the formation of strategic partnerships that have product development and manufacturing capabilities such as Elite. The phentermine HCl 37.5 mg product represents the first of these initiatives, and we expect an additional six product launches in the next six months. As the company sources products through development, acquisition and licensing opportunities, key areas of focus will be in the tablet, capsule and injectable dosage formats, with an emphasis on controlled substances, where there are additional barriers to entry. TAGI Pharma is located in South Beloit, Illinois, and additional information can be obtained from its website www.tagipharma.com.
MFG
Chali
Optionen
| Boardmail an "Chalifmann3" |
Wertpapier: Elite Pharmaceuticals |
Angehängte Grafik:
smilie_tanz_017.gif
smilie_tanz_017.gif
MFG
Chali
Optionen
| Boardmail an "Chalifmann3" |
Wertpapier: Elite Pharmaceuticals |
MFG
Chali
Optionen
| Boardmail an "Chalifmann3" |
Wertpapier: Elite Pharmaceuticals |
als Schwerpunkt Amimarkt Trader und von der schnellen Truppe habe ich Schäfchen schon im Trockenen Dank .11-.12 Kaufkurse (siehe link) :-DDDDDDDD $$$$$$
ý da sie aber so stark ist, bleibt sie unter strenger Beobachtung für Folgetrades... da drüben ist die Hölle los...
da bin ich auf dich gestoßen chali :-)
viel Glück allen... egal ob long oder Trader...
der Wert hat ganz schön Dampf... das muß man nutzen (nur meine Meinung, keine Empfehlung)
Grüße
Wes
dann kann man weiter sehen...
schaunmamal...
das ist o.k.
und dann schaunmamal wie sie sich weiter entwickelt...